Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.

Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.

<h4>Purpose</h4> <p>We have identified human medicinal products for which animal data were used as evidence for withdrawal, determined whether the adverse reactions were reported in humans, established whether confirmatory human studies were conducted, and explored the withdrawal...

Descripció completa

Dades bibliogràfiques
Autors principals:	Onakpoya, I, Heneghan, C, Aronson, J
Format:	Journal article
Idioma:	English
Publicat:	Wiley 2017

Ítems similars

Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
per: Onakpoya, I, et al.
Publicat: (2016)

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
per: Onakpoya, I, et al.
Publicat: (2016)

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
per: Onakpoya, IJ, et al.
Publicat: (2016)

Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
per: Onakpoya, I, et al.
Publicat: (2017)

Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
per: Igho J. Onakpoya, et al.
Publicat: (2019-03-01)

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
per: Onakpoya, I
Publicat: (2017)

Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
per: Onakpoya, I, et al.
Publicat: (2017)

The Adverse Drug Reactions Registered During the Postmarketing Period
per: E. V. Shubnikova, et al.
Publicat: (2019-03-01)

Rotavirus Vaccine Withdrawal in the United States: The Role of Postmarketing Surveillance
per: Gilles Delage
Publicat: (2000-01-01)

Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
per: Onakpoya, I, et al.
Publicat: (2018)

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
per: Colleen M. Kingsbury, et al.
Publicat: (2024-09-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
per: Wei Mao, et al.
Publicat: (2025-01-01)

Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
per: Daniele Sartori, et al.
Publicat: (2020-08-01)

Postmarket sequential database surveillance of medical products
per: Maro, Judith C
Publicat: (2013)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
per: Yamin Shu, et al.
Publicat: (2023-05-01)

Postmarket Surveillance of Neuroendovascular Devices
per: Marie K. Luff, et al.
Publicat: (2024-03-01)

Postmarket Drug Surveillance Without Trial Costs: Discovery of Adverse Drug Reactions Through Large-Scale Analysis of Web Search Queries
per: Yom-Tov, Elad, et al.
Publicat: (2013-06-01)

Redefining rapid reviews: a flexible framework for restricted systematic reviews
per: Plüddemann, A, et al.
Publicat: (2018)

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance
per: Jinyi Yuan, et al.
Publicat: (2022-12-01)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
per: John T. Sullivan
Publicat: (2022-04-01)

Naltrexone‐bupropion (Mysimba®) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
per: Onakpoya, IJ, et al.
Publicat: (2020)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
per: Kevin Wing, et al.
Publicat: (2019-10-01)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
per: Aronson, J
Publicat: (2008)

An agenda for research on adverse drug reactions.
per: Aronson, J
Publicat: (2007)

Adverse drug reactions--no farewell to harms.
per: Aronson, J
Publicat: (2007)

Pharmacogenetics and adverse drug reactions
per: Ferner, R, et al.
Publicat: (2010)

Clinical efficacy and safety of alemtuzumab in postmarketing practice
per: N. V. Khachanova
Publicat: (2019-06-01)

Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance
per: Goeun Park, et al.
Publicat: (2020-08-01)

Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014–19
per: Pasquale Stefanizzi, et al.
Publicat: (2022-01-01)

Postmarketing Surveillance: Review of Open Sources of Drug Safety Data
per: E. V. Shubnikova
Publicat: (2024-10-01)

Serum trough level as a postmarketing quality measure of generic vancomycin products
per: Ya-Wen Tsai, et al.
Publicat: (2020-04-01)

The need for randomization in animal trials: an overview of systematic reviews
per: Hirst, J, et al.
Publicat: (2014)

Orphan Therapies: Making Best Use of Postmarket Data
per: Li, Lingling, et al.
Publicat: (2016)

Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis
per: Huqun Li, et al.
Publicat: (2025-01-01)

Pharmacoepidemiology – Assessing the Risks and Benefits of Drugs in the Postmarketing Phase
per: Christoph R. Meier
Publicat: (2006-02-01)

Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials.
per: Onakpoya, I, et al.
Publicat: (2014)

Adverse drug reactions: definitions, diagnosis, and management.
per: Edwards, I, et al.
Publicat: (2000)

Reduced salt intake for heart failure: A systematic review
per: Mahtani, K, et al.
Publicat: (2018)

Postmarketing assessment of a switchable similar anastrozole product in Brazilian breast cancer patients
per: Manuela Vasquez Cardoso, et al.
Publicat: (2023-04-01)

Case reports of suspected adverse drug reactions--systematic literature survey of follow-up.
per: Loke, Y, et al.
Publicat: (2006)